ORLANDO, Fla. — Frank Sellke, MD, chief of the division of cardiothoracic surgery at the Warren Alpert Medical School of Brown University and Rhode Island Hospital, discusses results from an NIH-sponsored trial comparing repair vs. replacement for severe ischemic mitral valve regurgitation.
“A lot of surgeons and cardiologists are wondering how to treat these patients,” he said. “The researchers felt that, perhaps with time, repair would be found advantageous over replacement. At 2 years at least, that doesn’t seem to be the case.”
Besides detailing data on the recurrent severe mitral valve regurgitation between the two groups, Selke discusses the rates of readmissions for HF.
“We will have to follow these patients for much longer — hopefully 5 or even 10 years — before we have the real answers.”